I don't think I'm right, I am optimistic, but acknowledge that this will definitely not be a monopoly for AHZ. From all reports though, Cardiocel will gain considerable market share as it is deemed to be better than others, which obviously will be very profitable.
Some people see the glass half full and others half empty, both reasonable approaches. But for some reason Meerkat, something about AHZ has really annoyed you and you just can't see water in the glass at all
I don't think I'm right, I am optimistic, but acknowledge that...
-
- There are more pages in this discussion • 169 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
0.000(0.00%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191 | $17.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.55 | 2592 | 2 |
View Market Depth
| Last trade - 16.14pm 23/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |
Day chart unavailable